Avak Kahvejian (Flagship Pioneering)
May 10, 2021 06:30 AM EDTUpdated 07:22 AM
Financing
Startups

The com­pa­ny be­hind Mod­er­na has a new RNA start­up look­ing to dis­rupt drug­mak­ing. The goal? 100 new drugs in 10 years

Kyle Blankenship

When Flag­ship Pi­o­neer­ing propped up a small re­search team back in 2017 to study a lit­tle-known cir­cu­lar form of RNA, it wasn’t ex­act­ly a high …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times